Corvus Pharmaceuticals, Inc.
NASDAQCorvus Pharmaceuticals heads into its August 4 earnings report with nearly a quarter of its free float sold short — one of the more charged setups in small-cap biotech right now. Short sellers hold 23.9% of CRVS's free float, a level that has barely budged over the past month but has eased roughly 4.4% week-on-week as some bears trimmed positions. Days to cover is a lengthy 12.6…
Snapshot as of 16 Aug 2026
Corvus Pharmaceuticals heads into its August 4 earnings report with nearly a quarter of its free float sold short — one of the more charged setups in small-cap biotech right now. Short sellers hold 23.9% of CRVS's free…
CRVS enters July with a striking contradiction at its core: the stock has rallied 18% in a week and 20% over the past month to close at $14.94, yet short sellers have not retreated — they have added to positions. Short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CRVS — free to start on ORTEX.
Sign up for free →Open CRVS on ORTEX